๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Herpes simplex virus transcriptional activator VP16 is detrimental to preimplantation development in mice

โœ Scribed by Y. Gloria Yueh; Paul J. Yaworsky; Claudia Kappen


Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
266 KB
Volume
55
Category
Article
ISSN
1040-452X

No coin nor oath required. For personal study only.

โœฆ Synopsis


The herpes simplex virus transactivator protein VP16 is frequently used to regulate gene expression in several experimental systems, including transgenic mice. It has been suggested that high levels of VP16 expression in mice may be lethal. In order to systematically address this issue, we linked the VP16 gene to promoters that are active early and in a variety of tissues throughout development, such as the human โค-actin promoter or the rat nestin gene enhancer. VP16 expression was assayed using a LacZ reporter gene linked to a VP16-responsive immediate early gene promoter. We show here that expression of VP16 at high levels is detrimental to pre-implantation development. By culturing embryos in vitro, we demonstrate that this effect is exerted at the transition from the 2-cell to the 4-cell stage, reducing survival to the blastocyst stage dramatically. On the other hand, transgenic mice expressing VP16 transgenes at postimplantation stages are viable. These results suggest a differential sensitivity to VP16 expression in different cell types and stages of development. The reduction of embryo survival by VP16 implicates herpes virus infection as a potential cause of infertility.


๐Ÿ“œ SIMILAR VOLUMES


Natural resistance of BALB/c mice to her
โœ J. D. Claus; C. E. Coto; R. A. de Torres ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 165 KB ๐Ÿ‘ 1 views

Adult BALB/c mice, genetically resistant to HSV-1 i.p. infection, were inoculated intraperitoneally with 1000 PFU of HSV-1 and treated by the same route with four consecutive doses of Melia azedarach L. aqueous green leaves extract (MA) each containing 80 antiviral units against HSV-1 replication in